Alcoholic Hepatitis Network Observational Study

Exclusion Criteria

• •1. Liver disease significantly caused by hemochromatosis, autoimmune liver disease, Wilson disease, and acute viral hepatitis (NOTE: The presence of chronic hepatitis C, hepatitis B, HIV, or stage 1 (one lesion \<2 cm) HCC is not exclusion to participation)
• •2. Pregnant or breast feeding
• •3. Received liver transplant
• •4. Based on the judgment of the investigator, subject is not capable of understanding or complying with the study requirements
• •1. Past evidence of alcoholic liver disease, defined as a bilirubin \> 2.0 mg/dL, an AST \> 1.5 ULN, and any hospital admission for liver disease, or the presence of esophageal varices or ascites (at any time in the past)
• •2. Liver disease significantly caused by hemochromatosis, autoimmune liver disease, Wilson disease, NAFLD, and acute viral hepatitis (NOTE: The presence of chronic hepatitis C, hepatitis B, or HIV is not exclusion to participation.)
• •\*Individuals with a diagnosis of Gilbert's can have total bilirubin up to 3.0 mg/dL and still be eligible for participation.
• •3. Alcohol intake at less than 40 g/day or 280g/week on average for women and 60 g/day or 420 g/week on average for men for longer than the past 28 days
• •4. If liver stiffness has been assessed within the prior 90 days, then stiffness suggesting fibrosis of F1 or greater is excluded. For Fibroscan, this is a fibrosis score \>7.0 kPa.
• •5. Received liver transplant
• •6. Pregnant or breast feeding
• •7. Any of the following laboratory abnormalities within 90 days prior to signing the consent.
• •1. Total bilirubin: \>ULN\*
• •2. INR: \> 1.4
• •Healthy Controls
• •1. Clinical history or laboratory evidence of liver disease including alcoholic liver disease, NAFLD, hemochromatosis, alcoholic hepatitis, autoimmune liver disease, Wilson disease, hepatitis C, or hepatitis B.
• •2. Presence of diabetes (requiring treatment with oral agents or insulin).
• •3. Significant heart disease (prior history of heart disease, other than hypertension)
• •4. Chronic lung disease (requiring chronic treatment)
• •5. Immune related conditions (such as Crohn's disease, rheumatoid arthritis, ulcerative colitis, systemic lupus erythematosus, severe psoriasis, etc.)
• •6. Known infection with HIV
• •7. Presumed infection, or use of antibiotics or other medications (e.g., corticosteroids) that would affect immune function, within the past 14 days
• •8. BMI\>35
• •9. Current or known history of cancer (except in situ carcinoma of the cervix or adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior to enrollment
• •10. Received liver transplant
• •11. Pregnant or breast feeding
• •12. Any of the following laboratory abnormalities within 90 days prior to signing the consent.
• •1. Hemoglobin: \<10 g/dL
• •2. Conjugated bilirubin: \> ULN
• •3. INR: \> 1.4
• •4. AST: \>40 IU/mL
• •5. ALT: \>40 IU/mL
• •13. Based on the judgment of the investigator, subject is not capable of complying with the study requirements